Company intelligence / Profile preview
Aurealis Therapeutics
Zug, Zug, Switzerlandaurealistherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Aurealis Therapeutics has completed a Phase I trial and recently finished patient treatment in a Phase II trial of its lead product AUP‑16 for non-healing diabetic foot ulcers, with positive safety and efficacy data reported. The company has also published peer-reviewed results from its clinical studies. Its oncology candidate AUP‑55 targeting ovarian cancer and peritoneal carcinomatosis is in preclinical development. The company’s unique platform uses live genetically engineered lactic acid bacteria to deliver multiple therapeutic proteins directly at the disease site, acting as nanoscale drug bioreactors.[1][3][5][6]
- Therapeutic areas
- ImmunologyOncologyEndocrinologyCardiovascular
- Modalities
- Live biotherapeutic products (genetically modified lactic acid bacteria)Cell therapy (bacterial vector-based)Gene therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Licensing agreement with Chinese partner for AUP‑16 in China ($139M deal plus royalties); seeking further global/regional licensing partners.[3]Sponsorship of EWMA Diabetic Foot Committee.[1]
Beyond the preview
Go deeper on Aurealis Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aurealis Therapeutics.